ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Astellas Pharma, Inc.

  • 1,528.50 JPY
  • -23.00
  • -1.48%
  • Japan
    Jul 17, 2019
  • Ticker
    TKS(4503)
  • Prev. close
    1,551.5
  • Market cap (JPY)
    2,930.50B
  • Market cap (USD)
    27,066.67M
  • Shares
    1,888.82M

Business Summary

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue1,306.34B11,780.07M
Gross Profit979,086M8,828.97M
Operating income280,141M2,526.19M
Income before tax248,967M2,245.07M
Net income222,265M2,004.28M
EBITDA343,599M3,098.42M
Diluted EPS114.941.03
Dividends Per Share380.34
Total Assets1,897.64B17,144.58M
Total liabilities639,252M5,775.41M
Total equity1,258.39B11,369.16M
Operating cash flow261,428M2,357.44M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 1,247.25B 1,372.70B 1,311.66B 1,300.31B 1,306.34B
Gross Profit 875,398M 994,723M 955,325M 970,228M 979,086M
Operating income 216,283M 270,577M 276,419M 271,241M 280,141M
Income before tax 189,683M 261,770M 281,769M 218,113M 248,967M
Net income 135,856M 193,687M 218,701M 164,679M 222,265M
EBITDA 281,757M 339,765M 340,210M 336,104M 343,599M
Diluted EPS 61.40 89.62 103.55 81.02 114.94
Dividends Per Share 30 32 34 36 38
Total Assets 1,793.57B 1,799.33B 1,814.07B 1,858.20B 1,897.64B
Total liabilities 475,662M 540,129M 540,614M 583,608M 639,252M
Total equity 1,317.91B 1,259.20B 1,271.81B 1,268.28B 1,258.39B
Operating cash flow 189,977M 316,534M 237,230M 314,463M 261,428M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 11,353.53M 11,431.18M 12,112.80M 11,732.27M 11,780.07M
Gross Profit 7,968.55M 8,283.53M 8,822.11M 8,754.00M 8,828.97M
Operating income 1,968.77M 2,253.22M 2,552.63M 2,447.30M 2,526.19M
Income before tax 1,726.64M 2,179.88M 2,602.04M 1,967.95M 2,245.07M
Net income 1,236.66M 1,612.92M 2,019.63M 1,485.83M 2,004.28M
EBITDA 2,564.77M 2,829.38M 3,141.72M 3,032.54M 3,098.42M
Diluted EPS 0.55 0.74 0.95 0.73 1.03
Dividends Per Share 0.27 0.26 0.31 0.32 0.34
Total Assets 14,955.82M 16,009.05M 16,279.92M 17,472.54M 17,144.58M
Total liabilities 3,966.32M 4,805.63M 4,851.60M 5,487.61M 5,775.41M
Total equity 10,989.50M 11,203.42M 11,413.53M 11,925.61M 11,369.16M
Operating cash flow 1,729.31M 2,635.93M 2,190.74M 2,837.28M 2,357.44M

Valuation Measures

Mar 2019
PER14.41
ROA11.83%
ROE17.59%
Operating margin21.44%
Profit margin17.01%

Key executives

  • President, CEO & Representative Director: Kenji Yasukawa
  • Chief Financial Officer: Chikashi Takeda
  • SVP, Head-Innovation & New Technologies: Michael Rafa
  • General Manager-Pharmaceutical Technology: Mitsunori Matsuda
  • Executive Vice President & General Counsel: Linda Friedman

Shareholders

  • Nomura Asset Management Co., Ltd. (5.2%)
  • Nippon Life Insurance Co. (3.4%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.9%)
  • Nikko Asset Management Co., Ltd. (2.9%)
  • The Vanguard Group, Inc. (2.6%)
  • Daiwa Asset Management Co. Ltd. (2.4%)
  • BlackRock Fund Advisors (1.7%)
  • Norges Bank Investment Management (1.7%)
  • APG Asset Management NV (1.4%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (1.1%)

Contact Details

  • Website:http://www.astellas.com
  • Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
  • Phone: +81.3.3244.3000

Related Companies

  • Astellas Pharma, Inc. /Agensys Research Facilities/
  • Astellas Pharma, Inc. /16 Long Listed Products/
  • Astellas Farma Colombia
  • Astellas Pharma Director Incentive Plan
  • Quethera Ltd.
  • PT Astellas Pharma Indonesia
  • Astellas Pharma ZAO
  • Astellas Pharma ilac Ticaret ve Sanayi AS
  • Astellas Pharma Hong Kong Co. Ltd.
  • Astellas Pharma India Pvt Ltd.
  • Astellas Pharma Thailand Co. Ltd.
  • Astellas Pharma Australia Pty Ltd.
  • Astellas Pharma Singapore Pte Ltd.
  • Astellas Pharma Tech Co., Ltd.
  • Mitobridge, Inc.
  • Astellas Pharma China, Inc.
  • Perseid Therapeutics LLC
  • GPDC Partnership
  • Astellas Pharma Philippines, Inc.
  • Astellas Pharma Co. Ltd.
  • Astellas Pharma Canada, Inc.
  • Fujisawa Taiwan Co. Ltd.
  • Astellas Pharma SARL
  • Astellas Pharma Netherlands
  • Yamanouchi Health & Beauty Co. Ltd.
  • Yabrofarma Lda.
  • Fujisawa Ireland Ltd.
  • Astellas Pharma Korea, Inc.
  • Yamanouchi USA, Inc.
  • Astellas Pharma SP zoo

Competitors

  • AstraZeneca PLC
  • Hanmi Pharmaceutical Co., Ltd.
  • YungShin Global Holding Corp.
  • Ipsen SA
  • BioLineRX Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • AbClon, Inc.
  • Bicycle Therapeutics Plc Sponsored ADR
  • Coland Holdings Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Pieris Pharmaceuticals, Inc.
  • Mirati Therapeutics Inc.
  • Antares Pharma, Inc.
  • Trovagene, Inc.
  • Constellation Pharmaceuticals, Inc.
  • ESSA Pharma Inc
  • Sophiris Bio Inc.
  • Urovant Sciences Ltd.
  • Agios Pharmaceuticals, Inc.
  • Matinas BioPharma Holdings, Inc.
  • Cidara Therapeutics, Inc.
  • GlycoMimetics, Inc.
  • Oncternal Therapeutics, Inc.
  • Mersana Therapeutics, Inc.
  • Xenon Pharmaceuticals Inc.
  • ImmunoGen, Inc.
  • Kura Oncology, Inc.
  • Molecular Templates, Inc.
  • Five Prime Therapeutics, Inc.
  • Agenus Inc.
Last Updated on 17 Jul, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media